Meta Pixel

News and Announcements

IPO Investment Opportunity Closing Soon | Dealt Ltd has developed Australia’s first real-time Commercial Real Estate finance marketplace to assist borrowers to secure non-bank finance

  • Published April 22, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Click here to read more about the deal.

Highlights

  • 6.00% p.a. Target Distributions Paid Monthly
    Derived from multiple income sources with a focus on capital preservation
  • Technology Enabled Real Estate Lending
    Online lending platform with scalability including potential future overseas distribution agreements
  • Diverse Portfolio of RE Loans
    Diversified exposure to a portfolio of well-secured, Commercial Real Estate (CRE) senior loans throughout metropolitan Australia and New Zealand
  • Diversified Funding Sources
    Multiple capital options including warehouse facilities and private debt capital
  • Sponsor and Founders Co-Investment
    360 Capital Group and founders have committed up to 19.0% as co-investment capital
  • 15 -Year Real Estate Track Record360 Capital has never lost capital across its real estate lending activities. 360 Capital has transacted over $3 billion across the capital stack.

About Dealt Limited (ASX: DET)

Dealt Ltd (ASX: DET) has been established in response to the emergence of private, non-bank lenders in the $302 billion Australian and New Zealand Commercial Real Estate (CRE) lending market to provide alternative lending sources for borrowers.

Dealt has developed one of Australia’s first real time CRE finance marketplaces to assist borrowers to secure non-bank finance. The Group will also look to drive secure income returns through the development of a diversified portfolio of secured commercial real estate loans across Australia and New Zealand.

Register interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now